Safety, Tolerability, and Pharmacokinetics of ARM210 in Cardiac Arrhythmias: A Randomized, Placebo-Controlled Study in Healthy Subjects

The primary objective of this study is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of repeat doses of ARM210 in healthy subjects. This is clinically relevant as it provides essential data on the potential risks and bodily processing of ARM210, which is crucial for determining its suitability for further development and potential therapeutic use in conditions such as **cardiac arrhythmias**. Understanding these parameters is fundamental in ensuring that the drug can be safely administered to patients in future clinical settings.

The clinical trial focuses on participants diagnosed with **cardiac arrhythmias**. The study population includes both male and female subjects, encompassing an **age range** of 18 to 65 years. Participants are selected from a general health status that allows for the inclusion of a vulnerable population. However, the total number of participants has not been disclosed by the sponsor. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. Key inclusion or exclusion criteria have not been provided, and the main objective of the trial remains unspecified.

The clinical trial is a **randomized**, **placebo-controlled** study designed to evaluate the safety, tolerability, and pharmacokinetics of repeat doses of ARM210 in healthy subjects. The trial is conducted at a single center and is structured as a Phase 3 study. The estimated recruitment start date is February 27, 2024, with an anticipated end date of March 11, 2024. The study focuses on **cardiac arrhythmias**, a condition characterized by irregular heartbeats.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for inclusion in the trial. Following successful screening, participants will be randomly assigned to receive either the investigational product or a placebo in a double-blind manner, ensuring neither the participants nor the investigators know which treatment is being administered.

Throughout the trial, participants will attend scheduled follow-up visits to monitor their health status and collect data on the investigational product's effects. These visits will include assessments of safety, tolerability, and pharmacokinetics, as well as any adverse events. The end-of-study visit will mark the conclusion of the participant's involvement, during which final evaluations will be conducted to gather comprehensive data on the trial's outcomes.

The expected length of participant involvement is approximately two weeks, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design ensures rigorous monitoring and adherence to ethical standards, prioritizing participant safety and the integrity of the collected data.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is in Phase 3 and is scheduled to begin recruitment on February 27, 2024, with an estimated end date of March 11, 2024. The efficacy of the investigational treatment will be assessed through a series of predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent and reliable. The trial's design will likely include regular assessments at various timepoints throughout the study duration to monitor the treatment's impact on the disease. The use of validated scales, laboratory tests, or patient-reported outcomes may be employed to gather comprehensive efficacy data, although specific tools or instruments are not mentioned. The trial will adhere to rigorous standards to ensure the integrity and validity of the efficacy assessments.